Priyanka Upadhyay
Overview
Explore the profile of Priyanka Upadhyay including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
149
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Nandi S, Upadhyay P, Roy A, Dasgupta A, Sen A, Adhikary A, et al.
Environ Toxicol
. 2021 Sep;
37(1):52-68.
PMID: 34581487
Although comprehensive exertions have been made in late decades for treating advanced lung cancer with inclusive therapies but efficient anti-lung cancer therapeutics are statically inadequate in the clinics. Hence, compelling...
12.
Ghosh A, Upadhyay P, Sarker S, Das S, Bhattacharjee M, Bhattacharya S, et al.
Biomater Sci
. 2021 Jul;
9(16):5665-5690.
PMID: 34259681
To date, most of the accessible therapeutic options are virtually non-responsive towards triple-negative breast cancer (TNBC) due to its highly aggressive and metastatic nature. Interestingly, chemotherapy reacts soundly in many...
13.
Basu A, Upadhyay P, Ghosh A, Bose A, Gupta P, Chattopadhyay S, et al.
Biochim Biophys Acta Gen Subj
. 2021 Jan;
1865(3):129841.
PMID: 33412224
Background: Triple negative breast cancer (TNBC) is the most aggressive form of breast cancer with limited treatment modalities. It is associated with high propensity of cancer recurrence. Methods: UV Spectroscopy,...
14.
Basu A, Upadhyay P, Ghosh A, Chattopadhyay D, Adhikary A
ACS Biomater Sci Eng
. 2021 Jan;
5(1):373-389.
PMID: 33405856
Triple negative breast cancer (TNBC), characterized by its aggressive and highly metastatic nature, is difficult to cure by the currently available therapies. In our investigation, folic-acid-adorned PEGylated graphene oxide (FA-PEG-GO)...
15.
Bhattacharjee M, Upadhyay P, Sarker S, Basu A, Das S, Ghosh A, et al.
Biochim Biophys Acta Gen Subj
. 2020 Aug;
1864(11):129695.
PMID: 32735937
Background: Breast cancer intimidates the contemporary medical advances, attempting to revolutionize cancer therapeutics. While patients suffering an advanced breast cancer are dependent on mono drugs, yet the build out of...
16.
Ahir M, Upadhyay P, Ghosh A, Sarker S, Bhattacharya S, Gupta P, et al.
Biomater Sci
. 2020 Apr;
8(10):2939-2954.
PMID: 32319481
The development of new therapeutic strategies to target triple-negative breast cancer (TNBC) is in much demand to overcome the roadblocks associated with the existing treatment procedures. In this regard, therapies...
17.
Upadhyay P, Sarker S, Ghosh A, Gupta P, Das S, Ahir M, et al.
Biomater Sci
. 2019 Aug;
7(10):4325-4344.
PMID: 31411213
Non-small cell lung carcinoma (NSCLC) is a highly lethal type of cancer with limited therapeutic avenues available to date. In the present study, we formulated PEGylated PLGA thymoquinone nanoparticles (TQ-Np)...
18.
Roy A, Sarker S, Upadhyay P, Pal A, Adhikary A, Jana K, et al.
Biochem Pharmacol
. 2018 Sep;
156:322-339.
PMID: 30170097
Potent anticancer activity coupled with absence of toxicity at therapeutic dose established the glycolytic metabolite, methylglyoxal, as a promising candidate against malignant neoplasia. In this preclinical study we illustrate the...